Related references
Note: Only part of the references are listed.Decitabine facilitates the generation and immunosuppressive function of regulatory γδT cells derived from human peripheral blood mononuclear cells
Y. Hu et al.
LEUKEMIA (2013)
Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2013)
Six-of-the-best: unique contributions of γδ T cells to immunology
Pierre Vantourout et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Human Vγ9Vδ2 T Cells Specifically Recognize and Kill Acute Myeloid Leukemic Blasts
Julie Gertner-Dardenne et al.
JOURNAL OF IMMUNOLOGY (2012)
Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro
Haishan Li et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation
A. Kreutzman et al.
LEUKEMIA (2011)
The BCR/ABL-inhibitors Imatinib, Nilotinib and Dasatinib differentially affect NK cell reactivity
Julia Salih et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Vγ9Vγ2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells
Matilde D'Asaro et al.
JOURNAL OF IMMUNOLOGY (2010)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2009)
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets
Uwe Rix et al.
BLOOD (2007)
Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer
Francesco Dieli et al.
CANCER RESEARCH (2007)
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
Ellen Weisberg et al.
NATURE REVIEWS CANCER (2007)
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients
B Peng et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Lack of CD27-CD45RA-Vγ9Vδ2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis
C Gioia et al.
JOURNAL OF IMMUNOLOGY (2002)
Share Paper
